Novel agents for myeloma related bone disease
Why patients should be involved in evaluating novel drugs in multiple myeloma
What does the TOURMALINE-MM2 study tell us about the use of ixazomib in multiple myeloma?
What leads to shorter progression-free survival in CLL patients?
Defibrotide: Redefining the treatment for severe veno-occlusive disease (sVOD)